{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:18:45Z","timestamp":1793053125993,"version":"4.5.0"},"reference-count":84,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000081","name":"Danone Institute of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Rheumatoid arthritis (RA) is currently diagnosed and treated when an individual presents with signs and symptoms of inflammatory arthritis (IA) as well as other features, such as autoantibodies and\/or imaging findings, that provide sufficient confidence that the individual has RA\u2010like IA (e.g., meeting established classification criteria) that warrants therapeutic intervention. However, it is now known that there is a stage of seropositive RA during which circulating biomarkers and other factors (e.g., joint symptoms) can be used to predict if and when an individual who does not currently have IA may develop future clinically apparent IA and classifiable RA. Indeed, the discovery of the \u201cpre\u2010RA\u201d stage of seropositive disease has led to the development of several clinical trials in which individuals are studied to identify ways to delay or prevent the onset of clinically apparent IA\/RA. This review focuses on several issues pertinent to understanding the prevention of RA. These include discussion of the pathogenesis of pre\u2010RA development, prediction of the likelihood and timing of future classifiable RA, and a review of completed and ongoing clinical trials in RA prevention. Furthermore, this review discusses challenges and opportunities to be addressed to effect a paradigm shift in RA, where in the near future, proactive risk assessment focused on prevention of RA will become a public health strategy in much the same manner as cardiovascular disease is managed today.<\/jats:p>","DOI":"10.1002\/art.41417","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T03:23:55Z","timestamp":1593487435000},"page":"181-193","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":240,"title":["Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-4861","authenticated-orcid":false,"given":"Kevin D.","family":"Deane","sequence":"first","affiliation":[{"name":"University of Colorado Denver School of Medicine  Aurora Colorado United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7746","authenticated-orcid":false,"given":"V. Michael","family":"Holers","sequence":"additional","affiliation":[{"name":"University of Colorado Denver School of Medicine  Aurora Colorado United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000870"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024361"},{"key":"e_1_2_3_8_1","first-page":"613","article-title":"Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi\u2010dimensional remission criteria and patient reported outcomes","volume":"59","author":"Gul HL","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23518"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780311004"},{"key":"e_1_2_3_11_1","first-page":"2743","article-title":"Antifilaggrin antibodies within \"normal\" range predict rheumatoid arthritis in a linear fashion","volume":"27","author":"Aho K","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_3_12_1","first-page":"512","article-title":"Rheumatoid factor detection in the unaffected first degree relatives in families with multicase rheumatoid arthritis","volume":"18","author":"Silman AJ","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11223"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076679"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39297"},{"key":"e_1_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140767"},{"key":"e_1_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27570"},{"key":"e_1_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035296"},{"key":"e_1_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3237"},{"key":"e_1_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0638-x"},{"key":"e_1_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41091"},{"key":"e_1_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40562"},{"key":"e_1_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27186"},{"key":"e_1_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27638"},{"key":"e_1_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40920"},{"key":"e_1_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207991"},{"key":"e_1_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.08.003"},{"key":"e_1_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21575"},{"key":"e_1_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202127"},{"key":"e_1_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38273"},{"key":"e_1_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0070-0"},{"key":"e_1_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200990"},{"key":"e_1_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205227"},{"key":"e_1_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24833"},{"key":"e_1_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40880"},{"key":"e_1_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2013.28.1.45"},{"key":"e_1_2_3_38_1","first-page":"41","article-title":"Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials","volume":"27","author":"Gonzalez\u2010Lopez L","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105767"},{"key":"e_1_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212763"},{"key":"e_1_2_3_41_1","unstructured":"National Institute of Allergy and Infectious Diseases sponsor.Strategy to prevent the onset of clinically\u2010apparent rheumatoid arthritis (StopRA). Clinicaltrials.gov identifier: NCT02603146;2020."},{"key":"e_1_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3403-7"},{"key":"e_1_2_3_43_1","unstructured":"Amsterdam Rheumatology & immunology Center sponsor.Statins to prevent rheumatoid arthritis (STAPRA). Netherlands Trial Register: NL5036;2020."},{"key":"e_1_2_3_44_1","unstructured":"Leiden University Medical Centre sponsor.Treat early arthralgia to reverse or limit impending exacerbation to rheumatoid arthritis (TREAT EARLIER). Netherlands Trial Register: NL4599;2020."},{"key":"e_1_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120736"},{"key":"e_1_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38017"},{"key":"e_1_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209846"},{"key":"e_1_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024380"},{"key":"e_1_2_3_49_1","first-page":"536","article-title":"Imaging in the preclinical phases of rheumatoid arthritis","volume":"38","author":"Zabotti A","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39749"},{"key":"e_1_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000922"},{"key":"e_1_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209991"},{"key":"e_1_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0293"},{"key":"e_1_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.180"},{"key":"e_1_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11069-0"},{"key":"e_1_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40490"},{"key":"e_1_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.04.021"},{"key":"e_1_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280219862313"},{"key":"e_1_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu159"},{"key":"e_1_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20853"},{"key":"e_1_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24085"},{"key":"e_1_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796017000579"},{"key":"e_1_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-0065"},{"key":"e_1_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226"},{"key":"e_1_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23411"},{"key":"e_1_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.04.015"},{"key":"e_1_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.04.013"},{"key":"e_1_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4144-8"},{"key":"e_1_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000800"},{"key":"e_1_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2014.07.016"},{"key":"e_1_2_3_71_1","article-title":"A model to determine the cost\u2010effectiveness of screening psoriasis patients for psoriatic arthritis","author":"Iragorri N","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23837"},{"key":"e_1_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209154"},{"key":"e_1_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.5394"},{"key":"e_1_2_3_75_1","first-page":"1278","article-title":"Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process","volume":"20","author":"Aho K","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/31.6.365"},{"key":"e_1_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27533"},{"key":"e_1_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24350"},{"key":"e_1_2_3_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202254"},{"key":"e_1_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex324"},{"key":"e_1_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex360"},{"key":"e_1_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2004.08.003"},{"key":"e_1_2_3_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13370"},{"key":"e_1_2_3_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060004"},{"key":"e_1_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34344"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.41417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.41417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:50:53Z","timestamp":1759953053000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.41417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/art.41417"],"URL":"https:\/\/doi.org\/10.1002\/art.41417","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"assertion":[{"value":"2020-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}